<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39384241</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.</ArticleTitle><Pagination><StartPage>e087431</StartPage><MedlinePgn>e087431</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e087431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-087431</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Pregnant women with COVID-19 are at elevated risk for severe outcomes, but clinical data on management of these patients are limited. Monoclonal antibodies, such as casirivimab plus imdevimab (CAS+IMD), have proven effective in treating non-pregnant adults with COVID-19, prompting further evaluation in pregnant women.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A phase 3 portion of an adaptive, multicentre, randomised, double-blind, placebo-controlled trial evaluated the safety, clinical outcomes, pharmacokinetics and immunogenicity of CAS+IMD (1200 mg or 2400 mg) in the treatment of pregnant outpatients with COVID-19 (NCT04425629). Participants were enrolled between December 2020 and November 2021, prior to the emergence of Omicron-lineage variants against which CAS+IMD is not active. Safety was evaluated in randomised participants who received study drug (n=80); clinical outcomes were evaluated in all randomised participants (n=82). Only two pregnant participants received placebo, limiting conclusions regarding treatment effect. Infants born to pregnant participants were followed for developmental outcomes ≤1 year of age.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In pregnant participants, CAS+IMD was well tolerated, with no grade ≥2 hypersensitivity or infusion-related reactions reported. There were no participant deaths, and only one COVID-19-related medically attended visit. Although two pregnancies (3%) reported issues in the fetus/neonate, they were confounded by maternal history or considered to be due to an alternate aetiology. No adverse developmental outcomes in infants ≤1 year of age were considered related to in utero exposure to the study drug. CAS+IMD 1200 mg and 2400 mg rapidly and similarly reduced viral loads, with a dose-proportional increase in concentrations of CAS+IMD in serum. Pharmacokinetics were consistent with that reported in the general population. Immunogenicity incidence was low.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CAS+IMD treatment of pregnant outpatients with COVID-19 showed similar safety, clinical outcomes and pharmacokinetic profiles to that observed in non-pregnant adults. There was no evidence of an impact on developmental outcomes in infants ≤1 year of age.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT04425629.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><Identifier Source="ORCID">0009-0004-5896-9057</Identifier><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA thomas.norton@regeneron.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakur</LastName><ForeName>Mazhar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganguly</LastName><ForeName>Samit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Shazia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldron</LastName><ForeName>Alpana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Yogesh</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irvin</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atmodjo-Watkins</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Andrea T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Danise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchini</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Willis-Knighton Physician Network, Shreveport, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowal</LastName><ForeName>Bari</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiCioccio</LastName><ForeName>A Thomas</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhore</LastName><ForeName>Rafia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geba</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><Identifier Source="ORCID">0000-0001-8936-748X</Identifier><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunstein</LastName><ForeName>Ned</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Gary A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04425629</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711751">casirivimab and imdevimab drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>J0FI6WE1QN</RegistryNumber><NameOfSubstance UI="C000711487">casirivimab</NameOfSubstance></Chemical><Chemical><RegistryNumber>2Z3DQD2JHM</RegistryNumber><NameOfSubstance UI="C000711488">imdevimab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword></KeywordList><CoiStatement>Competing interests: TDN, MT, SG, SA, JC, AW, JX, JDD, SCI, CP, DA, DS, BK, ATD, RB, GPG, EC, NB and PD are employees and stockholders at Regeneron Pharmaceuticals, Inc. ATH is a Regeneron employee/stockholder and former Pfizer employee and current stockholder. KCT, JDH and GAH are Regeneron employees and stockholders, and have a patent pending, which has been licensed and receiving royalties, with Regeneron. JAB is a site PI for Regeneron Pharmaceuticals, Inc. multicentred clinical trials, Enanta multicentred clinical trials and Pfizer multicentred clinical trials; a sub-investigator for Novavax multicentred clinical trials; and an advisory board/panel member for Avalere, Pfizer, Moderna, Sobi and Valneva.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384241</ArticleId><ArticleId IdType="pmc">PMC11474922</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-087431</ArticleId><ArticleId IdType="pii">bmjopen-2024-087431</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372–4. doi: 10.1056/NEJMc2010419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2010419</ArticleId><ArticleId IdType="pmc">PMC7182018</ArticleId><ArticleId IdType="pubmed">32302078</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052–9. doi: 10.1001/jama.2020.6775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) Braz J Implantol Health Sci. 2020</Citation></Reference><Reference><Citation>Rahimi Pordanjani S, Hasanpour A, Askarpour H, et al. Aspects of epidemiology, pathology, virology, immunology, transmission, prevention, prognosis, diagnosis, and treatment of COVID-19 pandemic: A narrative review. Int J Prev Med. 2021;12:38. doi: 10.4103/ijpvm.IJPVM_469_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijpvm.IJPVM_469_20</ArticleId><ArticleId IdType="pmc">PMC8218815</ArticleId><ArticleId IdType="pubmed">34249287</ArticleId></ArticleIdList></Reference><Reference><Citation>Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3320</ArticleId><ArticleId IdType="pmc">PMC7459193</ArticleId><ArticleId IdType="pubmed">32873575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinn J, Sedighim S, Kirby KA, et al. Characteristics and outcomes of women with COVID-19 giving birth at US academic centers during the COVID-19 pandemic. JAMA Netw Open. 2021;4:e2120456. doi: 10.1001/jamanetworkopen.2021.20456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.20456</ArticleId><ArticleId IdType="pmc">PMC8358731</ArticleId><ArticleId IdType="pubmed">34379123</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz TD, Clifton RG, Hughes BL, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19) Obstet Gynecol. 2021;137:571–80. doi: 10.1097/AOG.0000000000004339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000004339</ArticleId><ArticleId IdType="pmc">PMC7984765</ArticleId><ArticleId IdType="pubmed">33560778</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175:817–26. doi: 10.1001/jamapediatrics.2021.1050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.1050</ArticleId><ArticleId IdType="pmc">PMC8063132</ArticleId><ArticleId IdType="pubmed">33885740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan NN, Kesarwani S, Kumbhar P, et al. Increased risk of early-onset preeclampsia in pregnant women with COVID-19. Hypertens Pregnancy. 2023;42:2187630. doi: 10.1080/10641955.2023.2187630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10641955.2023.2187630</ArticleId><ArticleId IdType="pubmed">36891839</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith ER, Oakley E, Grandner GW, et al. Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis. BMJ Glob Health. 2023;8:e009495. doi: 10.1136/bmjgh-2022-009495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2022-009495</ArticleId><ArticleId IdType="pmc">PMC9895919</ArticleId><ArticleId IdType="pubmed">36646475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779–84.e5. doi: 10.1016/j.molcel.2020.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.04.022</ArticleId><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–51. doi: 10.1056/NEJMoa2035002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton T, Ali S, Sivapalasingam S, et al. REGEN-cov antibody combination in outpatients with covid-19 – phase 1/2 results. Infectious Diseases (except HIV/AIDS) doi: 10.1101/2021.06.09.21257915. Preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.09.21257915</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385:NEJMoa2108163. doi: 10.1056/NEJMoa2108163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108163</ArticleId><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>Richley M, Rao RR, Afshar Y, et al. Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: A case series. Obstet Gynecol. 2022;139:368–72. doi: 10.1097/AOG.0000000000004689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000004689</ArticleId><ArticleId IdType="pmc">PMC8843364</ArticleId><ArticleId IdType="pubmed">35115451</ArticleId></ArticleIdList></Reference><Reference><Citation>Thilagar BP, Ghosh AK, Nguyen J, et al. Anti-spike monoclonal antibody therapy in pregnant women with mild-to-moderate coronavirus disease 2019 (COVID-19) Obstet Gynecol. 2022;139:616–8. doi: 10.1097/AOG.0000000000004700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000004700</ArticleId><ArticleId IdType="pmc">PMC8936149</ArticleId><ArticleId IdType="pubmed">35026789</ArticleId></ArticleIdList></Reference><Reference><Citation>Manciulli T, Modi G, Campolmi I, et al. Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy. Infection. 2022;50:1139–45. doi: 10.1007/s15010-022-01777-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01777-z</ArticleId><ArticleId IdType="pmc">PMC8900641</ArticleId><ArticleId IdType="pubmed">35257291</ArticleId></ArticleIdList></Reference><Reference><Citation>Magawa S, Nii M, Maki S, et al. Evaluation of the tolerability of monoclonal antibody therapy for pregnant patients with COVID-19. J Obstet Gynaecol Res. 2022;48:2325–33. doi: 10.1111/jog.15338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jog.15338</ArticleId><ArticleId IdType="pmc">PMC9349551</ArticleId><ArticleId IdType="pubmed">35748316</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey NH, Forrest AD, Spielman DW, et al. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic. Am J Obstet Gynecol MFM. 2022;4:S2589-9333(22)00108-2. doi: 10.1016/j.ajogmf.2022.100673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajogmf.2022.100673</ArticleId><ArticleId IdType="pmc">PMC9166252</ArticleId><ArticleId IdType="pubmed">35671984</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams FB, Morgan JA, Elmayan A, et al. Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce the risk of COVID-19 hospitalization in pregnancy: a retrospective cohort study. Am J Obstet Gynecol. 2023;228:102–3. doi: 10.1016/j.ajog.2022.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2022.09.017</ArticleId><ArticleId IdType="pmc">PMC9464623</ArticleId><ArticleId IdType="pubmed">36108732</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Unpacking Variants. 2022. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/04222022.html Available.</Citation></Reference><Reference><Citation>Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. 2021;184:3949–61. doi: 10.1016/j.cell.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8179113</ArticleId><ArticleId IdType="pubmed">34161776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature New Biol. 2021;593:130–5. doi: 10.1038/s41586-021-03398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvin SC, Ganguly S, Weiss R, et al. REGEN-COV antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification. Bioanalysis. 2021;13:1827–36. doi: 10.4155/bio-2021-0190.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2021-0190</ArticleId><ArticleId IdType="pmc">PMC8579949</ArticleId><ArticleId IdType="pubmed">34743612</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. 2023. https://www.fda.gov/media/149534/download Available.</Citation></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–44. doi: 10.1001/jama.2021.0202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0202</ArticleId><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2022;399:665–76. doi: 10.1016/S0140-6736(22)00163-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00163-5</ArticleId><ArticleId IdType="pmc">PMC8830904</ArticleId><ArticleId IdType="pubmed">35151397</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226:68–89. doi: 10.1016/j.ajog.2021.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2021.07.009</ArticleId><ArticleId IdType="pmc">PMC8294655</ArticleId><ArticleId IdType="pubmed">34302772</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallach N, Segal Y, Agassy J, et al. Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study. PLoS One. 2022;17:e0270893. doi: 10.1371/journal.pone.0270893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0270893</ArticleId><ArticleId IdType="pmc">PMC9299339</ArticleId><ArticleId IdType="pubmed">35857758</ArticleId></ArticleIdList></Reference><Reference><Citation>McClymont E, Albert AY, Alton GD, et al. Association of SARS-CoV-2 infection during pregnancy with maternal and perinatal outcomes. JAMA. 2022;327:1983–91. doi: 10.1001/jama.2022.5906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.5906</ArticleId><ArticleId IdType="pmc">PMC9062768</ArticleId><ArticleId IdType="pubmed">35499852</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SQ, Bilodeau-Bertrand M, Liu S, et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021;193:E540–8. doi: 10.1503/cmaj.202604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.202604</ArticleId><ArticleId IdType="pmc">PMC8084555</ArticleId><ArticleId IdType="pubmed">33741725</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations) 2022. https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Available.</Citation></Reference><Reference><Citation>Santa Maria C, Aby J, Truong MT, et al. The superior labial frenulum in newborns: what is normal? Glob Pediatr Health. 2017;4 doi: 10.1177/2333794X17718896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2333794X17718896</ArticleId><ArticleId IdType="pmc">PMC5528911</ArticleId><ArticleId IdType="pubmed">28812052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr. 2016;10:67–83. doi: 10.4137/CMPed.S40070.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CMPed.S40070</ArticleId><ArticleId IdType="pmc">PMC4946587</ArticleId><ArticleId IdType="pubmed">27441006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>